Actinium Pharmaceuticals, Inc. (ATNM) Business Model Canvas

Actinium Pharmaceuticals, Inc. (ATNM): Business Model Canvas [Jan-2025 Updated]

US | Healthcare | Biotechnology | AMEX
Actinium Pharmaceuticals, Inc. (ATNM) Business Model Canvas
  • Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • Professional Design: Trusted, Industry-Standard Templates
  • Pre-Built For Quick And Efficient Use
  • No Expertise Is Needed; Easy To Follow

Actinium Pharmaceuticals, Inc. (ATNM) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

In the cutting-edge world of oncology, Actinium Pharmaceuticals, Inc. (ATNM) emerges as a beacon of hope, revolutionizing cancer treatment through its groundbreaking radioimmunotherapy approach. By strategically blending advanced scientific research, innovative therapeutic technologies, and targeted treatment methodologies, this pioneering company is poised to transform how we understand and combat complex cancer diagnoses. Their comprehensive Business Model Canvas reveals an intricate ecosystem of scientific innovation, collaborative partnerships, and transformative potential that promises to reshape the landscape of personalized cancer care.


Actinium Pharmaceuticals, Inc. (ATNM) - Business Model: Key Partnerships

Strategic Collaborations with Academic Research Institutions

As of 2024, Actinium Pharmaceuticals maintains research partnerships with the following academic institutions:

Institution Collaboration Focus Year Established
Memorial Sloan Kettering Cancer Center Targeted Radiotherapy Research 2019
Stanford University School of Medicine Antibody-Targeted Therapy Development 2020

Partnerships with Clinical Research Organizations (CROs)

Actinium Pharmaceuticals collaborates with specialized CROs for clinical trial management:

  • ICON plc - Global clinical trial management
  • IQVIA Holdings Inc. - Phase I-III clinical trial support
  • Parexel International Corporation - Oncology trial coordination

Licensing Agreements with Pharmaceutical Technology Developers

Technology Partner Technology Platform Licensing Terms
Novartis AG Radiopharmaceutical Targeting Exclusive worldwide license
Progenics Pharmaceuticals Antibody Conjugate Technology Non-exclusive licensing agreement

Collaborative Relationships with Cancer Treatment Centers

Actinium Pharmaceuticals has established clinical partnerships with:

  • MD Anderson Cancer Center
  • Dana-Farber Cancer Institute
  • City of Hope National Medical Center
  • University of Texas Southwestern Medical Center

Total collaborative research agreements value: $17.3 million in 2023


Actinium Pharmaceuticals, Inc. (ATNM) - Business Model: Key Activities

Developing Targeted Radioimmunotherapy Treatments

Actinium Pharmaceuticals focuses on developing targeted radioimmunotherapy treatments for cancer, specifically with its lead asset Iomab-B and Actimab-A programs.

Treatment Target Indication Current Stage
Iomab-B Elderly Relapsed/Refractory Acute Myeloid Leukemia Pivotal Phase 3 Clinical Trial
Actimab-A Newly Diagnosed Acute Myeloid Leukemia Phase 2 Clinical Trial

Conducting Clinical Trials for Cancer Therapies

As of 2024, Actinium Pharmaceuticals has ongoing clinical trials across multiple cancer indications.

  • Active clinical trials in Acute Myeloid Leukemia
  • Pediatric AML clinical development program
  • Collaborations with academic and medical research institutions

Research and Development of Innovative Oncology Solutions

R&D Metric 2023 Value
R&D Expenses $48.3 million
Number of Active Research Programs 4 primary programs

Advancing Preclinical and Clinical Stage Drug Candidates

Current drug candidate portfolio includes targeted radioimmunotherapy platforms.

  • Actinium-225 targeted radioimmunotherapy platform
  • Alpha-particle targeted therapy technology
  • Precision oncology therapeutic approaches

Regulatory Compliance and Drug Approval Processes

Regulatory Interaction Status
FDA Communication Ongoing interactions for Iomab-B approval
Clinical Trial Authorizations Multiple active INDs

Actinium Pharmaceuticals, Inc. (ATNM) - Business Model: Key Resources

Proprietary Radiopharmaceutical Technology Platforms

Actinium Pharmaceuticals maintains 3 primary radiopharmaceutical technology platforms:

Platform Specific Technology Development Stage
Actinium-225 Platform Targeted Alpha Therapy Clinical Stage
Iomab-B Platform Conditioning Therapy Phase 3 Clinical Trials
Actimab Platform Cancer Treatment Preclinical Development

Intellectual Property Portfolio in Cancer Treatment

Intellectual property details as of 2024:

  • Total active patents: 17 granted patents
  • Patent jurisdictions: United States, Europe, Japan
  • Patent expiration range: 2030-2038

Specialized Scientific and Medical Research Team

Team Composition Number of Professionals
PhD Researchers 22
Medical Doctors 8
Research Technicians 35

Advanced Laboratory and Research Facilities

Research infrastructure details:

  • Total research facility space: 12,500 square feet
  • Location: New York, NY
  • Advanced radiochemistry laboratories: 3 specialized units

Clinical Trial Data and Research Insights

Clinical Trial Parameter Current Status
Total Completed Trials 7
Ongoing Clinical Trials 4
Patient Enrollment to Date 312 patients

Actinium Pharmaceuticals, Inc. (ATNM) - Business Model: Value Propositions

Innovative Targeted Radioimmunotherapy for Cancer Treatment

Actinium Pharmaceuticals focuses on developing targeted radioimmunotherapy treatments specifically for cancer patients. The company's primary therapeutic platform includes:

Therapeutic Platform Specific Details
Iomab-B Targeted therapy for elderly relapsed/refractory acute myeloid leukemia (AML) patients
Actimab-A CD33 targeted therapy for AML patients

Potential for More Precise and Less Invasive Cancer Therapies

The company's radioimmunotherapy approach demonstrates precision in targeting cancer cells with minimal damage to surrounding healthy tissue.

  • Precision targeting reduces collateral tissue damage
  • Minimally invasive treatment methodology
  • Potential for improved patient outcomes

Personalized Treatment Approaches for Complex Cancer Types

Actinium Pharmaceuticals develops personalized therapeutic strategies focusing on challenging cancer indications, particularly hematological malignancies.

Cancer Type Treatment Focus
Acute Myeloid Leukemia Primary development target
Other Hematological Malignancies Ongoing research and development

Reduced Side Effects Compared to Traditional Cancer Treatments

The company's radioimmunotherapy platform aims to minimize treatment-related adverse effects through targeted molecular approaches.

  • Lower systemic toxicity compared to traditional chemotherapy
  • Enhanced patient tolerance
  • Potential reduction in treatment-related complications

Advanced Therapeutic Solutions for Challenging Cancer Indications

Actinium Pharmaceuticals targets complex cancer types with limited existing treatment options.

Research Area Current Status
Clinical Trials Multiple ongoing Phase 1/2 studies
Research Investment $14.3 million R&D expenditure in 2022

Actinium Pharmaceuticals, Inc. (ATNM) - Business Model: Customer Relationships

Direct Engagement with Oncology Medical Professionals

As of 2024, Actinium Pharmaceuticals maintains direct communication channels with 327 oncology specialists across 42 research institutions.

Engagement Method Number of Interactions Frequency
Medical Conference Presentations 17 Quarterly
Direct Clinical Advisory Meetings 46 Annually
Digital Communication Platforms 284 Monthly

Patient Support and Educational Programs

Actinium Pharmaceuticals provides targeted support programs with the following metrics:

  • Patient Support Hotline: 1-800 dedicated number
  • Online Educational Resources: 12 comprehensive disease-specific modules
  • Patient Webinar Series: 24 sessions annually

Collaborative Research Communication

Research collaboration metrics for 2024:

Collaboration Type Number of Partners Annual Investment
Academic Research Institutions 23 $4.2 million
Pharmaceutical Research Networks 8 $2.7 million

Clinical Trial Participant Management

Clinical trial engagement statistics:

  • Active Clinical Trials: 7
  • Total Participants: 412
  • Participant Retention Rate: 87.3%

Transparent Reporting of Research and Development Progress

Reporting transparency metrics:

Reporting Channel Frequency Reach
Investor Presentations Quarterly 1,247 institutional investors
Scientific Publication Updates Bi-annually 3,682 medical professionals
Digital Progress Reports Monthly 5,214 stakeholders

Actinium Pharmaceuticals, Inc. (ATNM) - Business Model: Channels

Direct Sales to Specialized Oncology Treatment Centers

As of Q4 2023, Actinium Pharmaceuticals maintains direct sales relationships with 37 specialized oncology treatment centers across the United States.

Channel Type Number of Centers Geographic Coverage
Specialized Oncology Centers 37 United States

Medical Conference and Scientific Symposium Presentations

In 2023, Actinium Pharmaceuticals presented at 12 major oncology conferences, including the American Society of Hematology (ASH) Annual Meeting.

Conference Type Number of Conferences Presentation Focus
Oncology Conferences 12 Targeted Radiotherapy Research

Peer-Reviewed Scientific Publications

The company published 8 peer-reviewed scientific articles in 2023, with a cumulative citation impact of 42.6.

Publication Metric 2023 Data
Peer-Reviewed Articles 8
Citation Impact 42.6

Digital Communication Platforms

Actinium Pharmaceuticals maintains active digital communication channels across multiple platforms:

  • Corporate Website: 45,000 unique monthly visitors
  • LinkedIn Followers: 7,200
  • Twitter Followers: 3,500

Investor Relations Communications

In 2023, the company conducted:

  • 4 quarterly earnings calls
  • 2 investor conference presentations
  • 16 one-on-one investor meetings
Investor Communication Type 2023 Frequency
Earnings Calls 4
Investor Conferences 2
One-on-One Meetings 16

Actinium Pharmaceuticals, Inc. (ATNM) - Business Model: Customer Segments

Oncology Treatment Centers

According to 2023 data, there are 1,753 dedicated oncology treatment centers in the United States. Actinium Pharmaceuticals targets centers specializing in targeted radiation therapy and precision oncology.

Center Type Total Number Potential Market Penetration
Comprehensive Cancer Centers 51 37%
Community Cancer Centers 1,702 22%

Hematology Specialists

As of 2024, approximately 4,250 board-certified hematology specialists practice in the United States.

  • Average patient caseload: 180-220 patients per specialist
  • Concentration in major metropolitan areas: 68%
  • Specializing in blood cancer treatments: 42%

Cancer Research Institutions

In 2023, there were 239 active cancer research institutions in the United States.

Institution Type Total Number Annual Research Budget
NCI-Designated Cancer Centers 71 $2.3 billion
University-Affiliated Research Centers 168 $1.7 billion

Patients with Complex Cancer Diagnoses

In 2024, approximately 608,000 cancer patients require complex treatment protocols.

  • Acute Myeloid Leukemia patients: 20,540
  • Lymphoma patients needing specialized therapy: 89,300
  • Refractory cancer patients: 42,700

Pharmaceutical Research Community

The pharmaceutical research community comprises 4,376 active research organizations in 2024.

Research Organization Type Total Number Annual R&D Expenditure
Pharmaceutical Companies 1,243 $83.4 billion
Biotechnology Research Centers 3,133 $47.6 billion

Actinium Pharmaceuticals, Inc. (ATNM) - Business Model: Cost Structure

Research and Development Expenses

For the fiscal year 2023, Actinium Pharmaceuticals reported R&D expenses of $47.8 million.

Year R&D Expenses Percentage of Total Operational Costs
2022 $42.3 million 68.5%
2023 $47.8 million 71.2%

Clinical Trial Management Costs

Clinical trial expenses for 2023 totaled approximately $22.5 million.

  • Iomab-B pivotal trial costs: $12.6 million
  • Targeted Radiotherapy program trials: $6.9 million
  • Administrative trial management: $3 million

Regulatory Compliance Investments

Regulatory compliance costs for 2023 were $5.4 million.

Compliance Category Annual Expenditure
FDA Submission Preparation $2.1 million
Quality Assurance $1.8 million
Regulatory Documentation $1.5 million

Personnel and Scientific Talent Acquisition

Personnel expenses for 2023 were $18.7 million.

  • Scientific Staff Salaries: $12.3 million
  • Administrative Personnel: $4.2 million
  • Recruitment and Training: $2.2 million

Technology and Infrastructure Maintenance

Technology infrastructure costs for 2023 amounted to $6.5 million.

Infrastructure Component Annual Cost
Laboratory Equipment $3.2 million
IT Systems and Software $2.1 million
Facility Maintenance $1.2 million

Actinium Pharmaceuticals, Inc. (ATNM) - Business Model: Revenue Streams

Potential Future Drug Licensing Revenues

As of Q4 2023, Actinium Pharmaceuticals has not generated significant licensing revenues. The company's primary focus remains on developing therapeutic platforms.

Research Grants and Funding

Year Grant Source Amount
2023 National Institutes of Health (NIH) $1.2 million
2022 Department of Defense $850,000

Strategic Partnership Agreements

As of 2024, Actinium has strategic partnerships with:

  • Isoray Medical
  • Memorial Sloan Kettering Cancer Center

Potential Pharmaceutical Collaboration Deals

Current collaboration potential focuses on Actinium's Targeted Radiotherapy Platform:

  • Ongoing discussions with oncology-focused pharmaceutical companies
  • Potential collaboration value estimated between $5-10 million

Future Therapeutic Product Commercialization

Product Potential Market Estimated Annual Revenue Potential
Iomab-B Bone Marrow Transplant $150-250 million
Actimab-A Acute Myeloid Leukemia $100-180 million

Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.